Amundi Has $821,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

Amundi reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 37.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,805 shares of the biotechnology company’s stock after selling 14,170 shares during the period. Amundi’s holdings in Exelixis were worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB increased its stake in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares during the period. Steward Partners Investment Advisory LLC increased its stake in Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares during the period. Oregon Public Employees Retirement Fund increased its stake in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock worth $1,937,000 after acquiring an additional 354 shares during the period. Principal Securities Inc. increased its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares during the period. Finally, V Square Quantitative Management LLC increased its stake in Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 425 shares during the period. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EXEL. Piper Sandler raised their price objective on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Bank of America lowered Exelixis from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. UBS Group lifted their price target on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Stephens reiterated an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Finally, BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $36.00 to $40.00 in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Stock Performance

Shares of EXEL opened at $37.06 on Thursday. The stock has a 50 day moving average price of $35.53 and a two-hundred day moving average price of $32.71. The firm has a market capitalization of $10.37 billion, a P/E ratio of 20.94, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity

In other news, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares of the company’s stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last three months. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.